Clinical Trial Update: A Trial of Early Detection of Molecular Relapse With Circulating Tumour DNA Tracking and Treatment With Palbociclib Plus Fulvestrant Versus Standard Endocrine Therapy in Patients With ER Positive HER2 Negative Breast Cancer [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating palbociclib plus fulvestrant for ER-positive, HER2-negative breast cancer, using circulating tumor DNA tracking to detect re…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Faslodex (fulvestrant) (fulvestrant)
• Ibrance (palbociclib) (palbociclib)

Snippet

Sponsor: Royal Marsden NHS Foundation Trust | Conditions: ER+ Breast Cancer, HER2-negative Breast Cancer | Phase 2 | Status: RECRUITING